选择性激光小梁成形术的临床研究进展

选择性激光小梁成形术（SLT）是治疗开角型青光眼的一种新型激光手术,它应用倍频Q-开关、波长532nm的Nd：YAG激光,选择性作用于色素性小梁组织达到降低眼压目的。目前SLT已被用于初诊、药物治疗无效、氩激光小梁成形术（ALT）后失败或小梁切除手术失败、残余性青光眼和激素性青光眼等多种开角型青光眼患者,其术后效果不尽相同。影响选择性激光小梁成形术疗效的因素包括患者的术前眼压、小梁网色素含量、术前抗青光眼药物的使用以及激光的应用范围等。选择性激光小梁成形术疗效的长期性及其重复治疗的效果尚需进一步的观察和研究。     

选择性激光小梁成形术治疗青光眼的临床观察

目的评价选择性激光小梁成形术(SLT)治疗原发性开角型青光眼(POAG)、正常眼压性青光眼(NTG)的疗效和安全性。方法选择局部用药眼压不能控制的原发性开角型青光眼20例(37眼),正常眼压性青光眼6例(10眼)。观察应用选择性激光小梁成形术后6个月眼压的变化。结果术后眼压平均降低幅度为4.86±2.14mmHg(24.04±10.21%),两组患眼的眼压在激光治疗后均有显著下降:开角型青光眼组术后6个月的眼压较术前平均下降5.44±2.32mmHg(24.90±11.09%);正常眼压性青光眼组平均下降2.71±1.12mmHg(19.06±7.19%)。术后暂时的眼压升高、前房炎症反应为常见的并发症。结论选择性激光小梁成形术具有降眼压效果明显、安全、实用、损伤小、可重复等特点,是治疗青光眼的一种较安全有效的方法。     

选择性激光小梁成形术治疗开角型青光眼的研究进展

激光用于青光眼的治疗已有近35a的历史。近年来,选择性激光小梁成形术(SLT)以其安全、有效降眼压、并发症少等优点逐渐成为开角型青光眼的首选治疗。选择性激光小梁成形术是治疗开角型青光眼的一种新型激光手术,它应用倍频Q-开关、波长532nm的Nd:YAG激光,选择性作用于色素性小梁组织达到降低眼压目的。与氩激光小梁成形术(argonlasertrabeculoplasty,ALT)相比,两者降眼压效果相似,但是相对于ALT对小梁网的凝固性损伤,SLT选择性作用于色素性小梁细胞,无凝固性损伤,对小梁网组织轻微破坏,是一种安全且可重复治疗的手段。     

选择性激光小梁成形术研究进展

激光治疗是青光眼治疗的重要手段之一。选择性激光小梁成形术（SLT）选择性作用于小梁网的色素细胞,避免了对周边组织的损害,同时可起到一定程度的降眼压作用,其机制复杂,目前尚不完全明确。相关研究显示,对于开角型青光眼,SLT具有与氩激光小梁成形术（ALT）以及药物治疗相似的效果,在部分复杂病例及闭角型青光眼中也显示了一定的降眼压作用,术后反应较轻,且可以重复操作,将会越来越受到重视。就SLT的原理、临床应用进展及其并发症等进行综述。     

180°氩激光小梁成形术治疗开角型青光眼

目的评价180°氩激光小梁成形术治疗药物控制不良开角型青光眼患者的有效性.方法24名患者27眼,用氩激光照射鼻侧180°小梁网非色素性与色素性小梁交界处.光斑直径50μm,脉宽0.1S,功率0.6～1.2W,光凝点数50～60.术前术后滴0.2%brimonidine控制术后一过性高眼压.结果随访1～13月,平均11±4月,术前,术后1周,6月,12月平均眼压分别为25.7±5.4mmHg,17.9±3.9mmHg,19.6±4.7mmHg,20.1±4.7mmHg.术后6月成功率为23/27(85.1%),术后12月20/27(74.1%).术后一过性高眼压发生率6/27(22%),只有1例眼压比术前高7mmHg.结论180°氩激光小梁成形术能有效地降低开角型青光眼患者的眼压.     

选择性激光小梁成形术

选择性激光小梁成形术（SLT）通过选择性作用于色素性小梁网以改善房水的流出通道，从而达到降低眼内压，治疗原发性开角型青光眼的目的。研究表明，SLT无热损伤、可重复治疗、降眼压疗效显而安全，是治疗原发性开角型青光眼的又一新措施。     

选择性激光小梁成形术治疗原发性青光眼

目的评价选择性激光小梁成形术治疗原发性开角型青光眼(primaryopenangleglaucome,POAG)及原发性闭角型青光眼(prionaryangleclosureglaucome,PACG)虹膜周切术后残余青光眼的疗效和安全性。方法前瞻性、非随机性选择局部用药眼压不能控制的原发性开角型青光眼患者(13例16眼),或已行周边虹膜切除或激光虹膜打孔术,房角大部开放而眼压高的原发性闭角型青光眼患者(22例32眼)。应用选择性激光小梁成形术治疗。观察患者术后6个月眼压的变化。结果两组患者的眼压在激光治疗后均有显著下降:POAG组由术前的(25.3±3.9)mmHg降低至术后6个月的(18.0±4.2)mmHg;PACG组由术前的(23.9±3.0)mmHg,降低至术后6个月的(18.8±3.8)mmHg(1kPa=7.5mmHg)。术后暂时的眼压升高为最常见的并发症。结论选择性激光小梁成形术不仅可用于原发性开角型青光眼的治疗,也可以作为治疗残余闭角型青光眼的一种安全有效的方法。     

选择性激光小梁成形术的研究进展

青光眼是全球第一大不可逆的致盲性眼病,通过药物、激光和手术降低眼压是治疗青光眼的基本方法。选择性激光小梁成形术(SLT)是应用倍频Q开关、波长532 nm的掺钕钇铝石榴石激光,选择性作用于色素性小梁组织达到降低眼压目的。近30年来,SLT在不引起小梁网凝固性损伤的情况下可以降低眼压,已经逐渐成为治疗以原发性开角型青光眼为主的各种类型青光眼的初始治疗或替代治疗方法之一。本文中笔者就SLT的历史沿革、降眼压机制、临床应用、初始治疗、重复治疗、治疗成功的预测因素、并发不良反应、成本效益及健康相关生活质量等方面进行综述。     

选择性激光小梁成形术治疗开角型青光眼

开角型青光眼(open angle glaucoma，OAG)的临床治疗是国内外眼科专家关注的课题之一。Wise和Witter 1979年首次报道氩激光小梁成形术(argonlaser trabecnlo plasty，ALT)可成功地降低眼压。2001年11月美国眼科学会会议上讨论了选择性激光小梁成形术(select laser trabecularplasty．SLT)对OAG治疗的有效性，美国FDA通过了SLT可以用于临床的报告。我     

开角型青光眼氩激光小梁成形术后眼压观察

为分析开角型青光眼在氩激光小梁成形术（ＡＬＴ）后的眼压变化情况，并探讨与青光眼种类、随访时间、患者年龄的关系。对２１例（３５眼）开角型青光眼患者，经药物治疗后眼压仍处在２３～３５ｍｍＨｇ范围内，行小梁后区１８０度或３６０度氩激光光凝治疗。术后随访１．５～６个月。结果：眼压控制率时间呈偏心性正态曲线分布，最佳控制效果在术后四周（控制率８４．７％），以后眼压呈上升的趋势，半年眼压控制率为５９．３％；原发性青光眼疗效显著高于继发性组（Ｐ＜０．０５）；４０岁以上年龄组疗效明显好于４０岁以下组（Ｐ＜０．０１），没有明显的并发症。结论：ＡＬＴ对药物控制不理想、但在３５ｍｍＨｇ以下的开角型青光眼可作为首选的降压治疗方法     

Selective laser trabeculoplasty

The introduction of selective laser trabeculoplasty (SLT) provided a new choice for the reduction of intraocular pressure (IOP) in eyes with open angle glaucoma (OAG) and ocular hypertension (OHT). SLT was demonstrated equally as effective as topical medical therapy and argon laser trabeculoplasty (ALT) to lower IOP. It is a potentially repeatable procedure because of the lack of coagulation damage to the trabecular meshwork (TM) and also effect in patients with previously failed ALT. SLT can be used to treat patients with OAG, pseudoexfoliation glaucoma, pigmentary glaucoma, normal-tension glaucoma, OHT, juvenile glaucoma, pseudophakic and aphakic glaucoma. Furthermore, SLT can be considered as a primary treatment option in patients who cannot tolerate or are noncompliant with medications, while not interfering with the success of future surgery. Its safety profiles include mild and transient inflammation, ocular pain and a small risk of moderate IOP elevations after the procedure. SLT is a safe and effective means of IOP reduction in eyes with OAG and OHT.     

Selective laser trabeculoplasty retreatment after prior argon laser trabeculoplasty: 1-year results

BACKGROUND: Argon laser trabeculoplasty (ALT) and selective laser trabeculoplasty (SLT) are treatments for open-angle glaucoma. Many patients have previously received ALT but could benefit from further treatment. The purpose of this study was to examine whether SLT provided clinical benefit for patients who had previously received complete argon treatment. METHODS: This was a prospective, partially randomized, comparison study. The study compared the effect after 1 year of SLT in patients with open-angle glaucoma (primary, pigmentary, or pseudoexfoliation) who had previously received 360 degrees of ALT with the effect of laser treatment (ALT or SLT) given for the first time in patients with this condition. Ninety-six subjects were given 180 degrees of laser trabeculoplasty. When both eyes qualified for treatment, the first eye treated was included in the analysis. Twenty-seven subjects were treated with SLT after previously receiving 360 degrees of ALT therapy; the remainder were given their first laser treatment, 30 being randomly assigned by coin toss to receive SLT and 39 to receive ALT. RESULTS: The mean intraocular pressure (IOP) before treatment was 21.5 mm Hg (SLT after ALT), 22.9 mm Hg (SLT), and 22.0 mm Hg (ALT), with no statistical difference among the groups (p > 0.05). The mean IOP at 1 year was 16.7 mm Hg (SLT after ALT), 17.1 mm Hg (SLT), and 16.4 mm Hg (ALT). The IOP for all 3 groups was statistically significantly lower than at baseline (p < 0.001), but there were no differences among the groups in this respect (p > 0.05). At 1 year, the percentage IOP reductions from baseline were 23% (SLT), 19.3% (SLT after ALT), and 24% (ALT). There were no differences among the groups in the number of medications used before the laser, although there was a small but statistically significant decrease in the number of medications used before or after the laser treatment in both the SLT and the SLT after ALT group, but not the ALT group. INTERPRETATION: SLT retreatment can produce a clinically useful decrease in IOP at 1 year, similar to that obtained by ALT, in patients who have had prior argon laser treatment. SLT may be a useful adjunctive therapy when 360 degrees of ALT has already been performed.     

选择性激光小梁成形术治疗原发性开角型青光眼的临床观察

目的:评价选择性激光小梁成形术(selective laser trabecu-loplasty,SLT)治疗原发性开角型青光眼的疗效和安全性及对不同条件原发性开角型青光眼治疗效果的差异。方法:原发性开角型青光眼46例46眼,分为A组(曾行小梁切除手术)21眼,B组(单纯药物治疗)14眼,C组(诊断未经治疗)11眼,经SLT治疗,随诊6mo,观察眼压、视力、视野等改变。结果:总体平均眼压在术后1d;1wk;1,3和6mo分别为(16.9±3.2),(18.7±3.3),(18.9±3.3),(19.8±3.2),(20.0±3.4)mmHg,均比术前眼压下降,具有显著性统计学差异,同一时间3组间比较无差异,术后反应均为一过性,1～3d内消失。结论:SLT治疗不同条件的原发性开角型青光眼均安全有效,长期疗效及重复治疗有待进一步观察。     

选择性激光小梁成形术对部分特殊类型高眼压患者的降压效果

目的:探讨选择性激光小梁成形术(selective laser trabecu-loplasty,SLT)对部分特殊类型眼压升高患者的降眼压效果。这些患者不适宜或者不接受抗青光眼手术治疗。方法:临床观察10例高眼压患者,其中硅油取出后无晶状体高眼压1例,青光眼术后3例(其中1例在阿塞拜疆行二次抗青光眼手术),未确诊青光眼的高眼压症3例,硅油充填术后1例,绝对期青光眼2例(其中开角1例,闭角1例),根据眼压范围行Nd:YAG激光SLT治疗(选择上方或下方180°范围内治疗,原发性闭角型青光眼行激光周边虹膜成形术和激光周边虹膜切除术后眼压>21mmHg的再行选择性激光小梁成形术)。结果:SLT10眼术前平均眼压28.9±5.4mmHg(眼压22～40mmHg);术后1d;1wk;1,6mo眼压分别为21.6±6.5mmHg,24.3±6.01mmHg,22.2±63mmHg,21.4±5.2mmHg。SLT术后6mo不用药物眼压≤21mmHg有6眼;部分患者需要重复治疗,全部患者加用1种降眼压药物眼压≤21mmHg,未出现明显的前房炎症反应,少部分患者在治疗时有轻微的疼痛及不适感。结论:SLT对于不适宜抗青光眼手术治疗的一些特殊类型的高眼压患者,是安全有效、费用低廉的可供选择的降眼压方法。     

选择性激光小梁成形术治疗原发性开角型青光眼

目的:选择性激光小梁成形术(selective laser trabeculoplasty,SLT)治疗原发性开角型青光眼(primary open angle glaucoma,POAG)观察。方法:原发性开角型青光眼80例160眼,蓝黄视野检查未见明显损害或轻度损害,眼压>30mmHg者20例40眼,眼压<30mmHg者60例120眼。使用倍频Q开关,波长532nm,Nd∶YAG激光,照射180°~360°小梁网,光斑400nm,脉宽3μs,能量设置0.3~1.0mJ。光斑点数50~80点,术后1d;1wk;1,3,6mo测眼压。结果:对于眼压在>30mmHg的POAG患者眼压控制不理想。眼压<30mmHg的POAG患者效果明显。结论:SLT的降眼压效果,虽然针对性较强,适宜患者人群窄,但给POAG的治疗提供了新思路和新希望。     

Selective laser trabeculoplasty

Selective laser trabeculoplasty (SLT) has been shown to be safe, well tolerated, and effective in intraocular pressure (IOP) reduction as therapy in several forms of open-angle glaucoma. The preservation of trabecular meshwork (TM) architecture and the demonstrated efficacy in lowering IOP make SLT a reasonable and safe alternative to argon laser trabeculoplasty (ALT). SLT may also be effective for cases of failed ALT and is a procedure that may also be repeatable, unlike ALT. SLT is also a simple technique for an ophthalmologist to learn as the large spot size eliminates the need to locate a particular zone of treatment on the TM. SLT has been demonstrated to be effective as primary treatment for open angle glaucoma and can be an effective adjunct in the early treatment of glaucoma. Furthermore, SLT can be considered as a primary treatment option in patients who cannot tolerate or who are noncompliant with their glaucoma medications, without interfering with the success of future surgery.     

Comparison of success rate and intraocular pressure spikes between selective laser trabeculoplasty and micropulse laser trabeculoplasty in African American and Hispanic patients

AIM: To examine the efficacy and safety of micropulse laser trabeculoplasty (MLT) versus selective laser trabeculoplasty (SLT) in a large cohort of primarily African American and Hispanic patients. METHODS: A single center retrospective comparative cohort review conducted at Cook County Health facilities that included patients with a diagnosis of open angle glaucoma or ocular hypertension who received an SLT or MLT procedure between January 2017 and May 2021. RESULTS: Totally 131 eyes of 99 patients were analyzed. The 77 eyes received SLT and 54 received MLT. Seven out of 77 eyes in the SLT group (9.1%) and 1 out of 54 eyes in the MLT group (1.9%) had an IOP spike (defined as > 5 mm Hg) at either 1h or 1wk after procedure (P=0.05, Chi-squared test with Haldane-Anscombe correction). The procedure failure rate at one year was 50% for SLT and 48% for MLT (P=0.31). CONCLUSION: MLT has a significantly lower incidence of pressure spikes and a similar treatment failure rate at 1-year post-procedure, demonstrating that it is a reasonable alternative compared to SLT.     

选择性激光小梁成形治疗开角型青光眼的疗效分析

目的 评价选择性激光小梁成形术治疗原发性开角型青光眼的疗效和安全性.方法 局部用药治疗的原发性开角型青光眼43只眼和高眼压症7只眼.使用Q开关倍频Nd:YAG激光实施180°小梁网激光照射.激光能量0.5～1.0 mJ,50～60个击射点.术后定期测量眼压和裂隙灯检查.随访期内仍然给予降眼压眼液.结果 平均随访8.6月(6～12月).术后所眼都有轻度前节炎症反应,3天后自然消退.术后继续使用降眼压眼液.A组(基线眼压17～24 mm Hg)和B组(基线眼压26～36 mm Hg)术后1、3、6、12月眼压下降幅度分别为30.1%、26.3%、25.6%、23.3%;和17%、21.5%、15%、10.9%,2组差异有显著性(P＜0.05).结论 SLT治疗开角青光眼的并发症是轻微的,降眼压的效果与术前眼压基线高低有关.

Abstract：

Objective To investigate the safety and efficacy of selective laser trabeculoplasty (SLT) in the treatment of open angle glaucoma.Methods Forty-three eyes with open-angle glaucoma and 7 eyes with ocular hypertension were treated withafrequency doubled Q-switched Nd:YAG laser.A total of 50～60 laser spots were placed over 180° of trabecular meshwork with energy levels ranging from 0.5 to 1.0mJ per pulse. Intraocular pressure measurement and slit lamp examination were regularly performed after laser surgery. Topical anti-glaucoma drug was given during the follow up period Results The follow up was 6～12 months (average 8.6 months). Slight inflammation of anterior chamber occurred in the all eyes, and disappeared 3 days later automatically. IOP reduction of group A (baseline IOP 17～24 mmHg) and groupB(baseline IOP 26-36 mmHg) was 30.1%, 26.3%, 25.6%,23.3%; and 17%, 21.5%. 15%, 10.9% at 1,3,6and 12 months, respectively. IOP reduction between two groups was significantly difference(P＜0.05). Conclusions Adverse effects of SLT for open angle glaucoma is a mild and temporary. Effect of lowing IOP isrelated to baseline pressure.     

Selective laser trabeculoplasty (SLT) vs other treatment modalities for glaucoma: systematic review

Purpose

Systemic review to compare selective laser trabeculoplasty (SLT) to other glaucoma treatment options in terms of their intraocular pressure (IOP)-lowering effect.

Methods

Searches of the following databases were performed: PubMed, Cochrane Central Register of Controlled Trials, Ovid, EMBASE, metaRegister of Controlled Trials, and ClinicalTrials.gov. Only randomised controlled trials (RCTs) published in peer-reviewed journals comparing SLT to other glaucoma treatment options were considered. The main outcome measure was the change in IOP from baseline.

Results

An initial search of PubMed identified 23 RCTs with 17 meeting the inclusion criteria. Nine RCTs compared 180° SLT to 180° argon laser trabeculoplasty (ALT) and one trial compared 360° SLT to 360° ALT, all reporting no difference in terms of IOP reduction from baseline. One RCT reported better outcomes with SLT at 1 year but this effect regressed at 2 years. Three trials compared 360° SLT to medical therapy and found no difference between the two treatment options. One trial found greater IOP reduction with latanoprost vs 90° and 180° SLT, and greater IOP reduction with 180° and 360° SLT versus 90° SLT, however no differences were found between 360° SLT versus latanoprost or 360° vs 180° SLT. Two trials compared 180° SLT to 360° SLT finding no difference in IOP reduction. Two trials compared 180° SLT to 90° SLT, one finding no significant difference and one finding greater IOP reduction with 180° SLT over 90° SLT. One trial compared excimer laser trabeculotomy (ELT) to 180° SLT, finding no differences in IOP reduction up to 3 months follow-up but greater IOP reduction with ELT at time intervals between 9 and 24 months. There were no RCTs identified that compared SLT to surgery.

Conclusion

In terms of the IOP lowering effect, there is no difference between SLT and ALT. Three trials indicate no difference between 360° SLT and medical therapy, with one of the trials indicating greater IOP reduction with latanoprost over 90° and 180° SLT. Three trials indicate no difference between 180° SLT and 360° SLT. It is inconclusive whether 90° is less efficacious than 180° SLT. One trial reports greater IOP reduction with ELT over 180° SLT in the long term.     

Evaluation of a modified protocol for selective laser trabeculoplasty

PURPOSE: To compare the intraocular pressure (IOP) response to a modified protocol for selective laser trabeculoplasty (SLT) to standard protocols for SLT and argon laser trabeculoplasty (ALT). MATERIALS AND METHODS: A retrospective study of 318 eyes of 284 patients diagnosed with either primary open angle, pigmentary or pseudoexfoliation glaucoma who underwent laser trabeculoplasty from September 1997 to September 2005. One hundred and two patients, who underwent a modified SLT protocol with 100 overlapping laser spots over 180 degrees of trabecular meshwork were compared with 89 patients who received SLT with 100 nonoverlapping spots over 360 degrees and another 127 patients who received ALT with 50 spots over 180 degrees. IOPs were measured at baseline and postoperatively at 1 hour, 6 weeks, 4 months, and 14 months. Regression models, based on the observed data, were used to predict the fall in IOP in the 3 groups, controlling for differences in baseline pressure. RESULTS: The IOP response to overlapping SLT was significantly worse than to nonoverlapping SLT or ALT, both of which had similar responses. Baseline IOP was the only preoperative factor that predicted response to ALT (P<0.0001) and nonoverlapping SLT (P=0.0019) at all follow-up times. There were no statistically significant predictive factors for IOP reduction in the overlapping SLT group. CONCLUSIONS: Overlapping application of SLT results in a poorer IOP response compared with ALT and nonoverlapping SLT.